<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545372</url>
  </required_header>
  <id_info>
    <org_study_id>P.T.REC/012/001072</org_study_id>
    <nct_id>NCT04545372</nct_id>
  </id_info>
  <brief_title>Aerobic Exercises for Multiple Sclerosis</brief_title>
  <official_title>Effect of Aerobic Exercises on Immune System in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central&#xD;
      nervous system (CNS) .It is the most common neurological disorders affecting young&#xD;
      adults.Multiple sclerosis is an autoimmune disease that results in progressive neural&#xD;
      degeneration. Cytokines play an important role in the pathogenesis and treatment of MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research aims to evaluate the effect of aerobic exercises on the immune system&#xD;
      anti-inflammatory (IL-10) and pro inflammatory (IL-17) cytokines and its consequences on the&#xD;
      functional status in the Multiple Sclerosis patients.&#xD;
&#xD;
      Aerobic exercises are a term to describe planned, structured and repetitive physical activity&#xD;
      undertaken over a prolonged period to maintain or improve physical fitness and functional&#xD;
      capacity .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Actual">August 6, 2020</completion_date>
  <primary_completion_date type="Actual">August 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>study group (GA) and control group (GB) in addition to normal matched subjects (GC).The control group (GB)was treated by the disease modifying drug (interferon beta-1a) &quot;Rebif&quot;, (GA) treated by the same drug in addition to a physical therapy program of aerobic exercises for 40 min included bicycle ergometry training</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator) Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (study group) and Group B (control group),</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>blood analysis</measure>
    <time_frame>serum anti inflammatory cytokine IL-10, will be assessed at 0 day</time_frame>
    <description>serum anti inflammatory cytokine IL-10,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood analysis</measure>
    <time_frame>serum anti inflammatory cytokine IL-10, wil lbe assessed at 90 day</time_frame>
    <description>serum anti inflammatory cytokine IL-10,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood analysis</measure>
    <time_frame>pro inflammatory cytokine IL-17 will be assessed at 0 day</time_frame>
    <description>pro inflammatory cytokine IL-17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood analysis</measure>
    <time_frame>pro inflammatory cytokine IL-17 will be assessed at 90 day</time_frame>
    <description>pro inflammatory cytokine IL-17</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <arm_group>
    <arm_group_label>the study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group (GB)was treated only by the disease modifying drug (interferon beta-1a)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>aerobic exercise</intervention_name>
    <arm_group_label>the study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        age ranged from 25 to 45 years. All the patients were remitting relapsing MS according to&#xD;
        (revised McDonald criteria.&#xD;
&#xD;
        Duration of MS disease was one to two years before starting of the study. Last attack&#xD;
        occurred three months ago. All patients were able to ambulate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with other neurological deficits , patient with significant orthopedic&#xD;
        abnormalities for both lower limbs, patient with contracture , patient with deformities,&#xD;
        pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nehad A. Abo-Zaid, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Valley University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heba A. Kalifa, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Valley University, Faculty of Physical Therapy</name>
      <address>
        <city>Qina,</city>
        <zip>83523</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Steensberg A, Fischer CP, Keller C, MÃ¸ller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E433-7.</citation>
    <PMID>12857678</PMID>
  </reference>
  <reference>
    <citation>Barry A, Cronin O, Ryan AM, Sweeney B, Yap SM, O'Toole O, Allen AP, Clarke G, O'Halloran KD, Downer EJ. Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology. Front Physiol. 2016 Jun 2;7:194. doi: 10.3389/fphys.2016.00194. eCollection 2016. Review.</citation>
    <PMID>27313534</PMID>
  </reference>
  <reference>
    <citation>Haegert DG. Multiple sclerosis: a disorder of altered T-cell homeostasis. Mult Scler Int. 2011;2011:461304. doi: 10.1155/2011/461304. Epub 2011 Sep 15.</citation>
    <PMID>22096637</PMID>
  </reference>
  <reference>
    <citation>Broughton SE, Hercus TR, Lopez AF, Parker MW. Cytokine receptor activation at the cell surface. Curr Opin Struct Biol. 2012 Jun;22(3):350-9. doi: 10.1016/j.sbi.2012.03.015. Epub 2012 Apr 20. Review.</citation>
    <PMID>22521507</PMID>
  </reference>
  <reference>
    <citation>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7.</citation>
    <PMID>11456302</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Nehad Ahmed Youness Abo-zaid</investigator_full_name>
    <investigator_title>Lecturer of physical therapy</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Aerobic exercises</keyword>
  <keyword>cytokine IL-10</keyword>
  <keyword>cytokine IL-17</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT04545372/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

